Auro Laboratories Limited (BOM:530233)
India · Delayed Price · Currency is INR | Market Cap | 1.57B +1.5% |
| Revenue (ttm) | 307.40M +58.5% |
| Net Income | 35.33M +92.1% |
| EPS | 5.67 +92.2% |
| Shares Out | 6.23M |
| PE Ratio | 44.37 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,370 |
| Open | 256.00 |
| Previous Close | 258.55 |
| Day's Range | 251.30 - 264.45 |
| 52-Week Range | 159.00 - 317.00 |
| Beta | 0.01 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 29, 2026 |
About Auro Laboratories
Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India. It offers antihistamine; muscle relaxant; diuretic; iron deficiency; anti-diabetic, including Metformin HCL; anti-fungal, ulcer, malaria, and inflammatory; iodine supplement; analgesics; antacids; potassium and sodium iodide; and microcrystalline cellulose. The company also provides specialty chemicals comprising guanidine nitrate; dimethyl amine HCl; 2-ethoxy benzoic acid; and 3,4,5 - trimethoxy benzoic a... [Read more]
Financial Performance
In fiscal year 2026, Auro Laboratories's revenue was 307.40 million, an increase of 58.47% compared to the previous year's 193.98 million. Earnings were 35.33 million, an increase of 92.14%.
Financial StatementsNews
Shaan Jain resigns as CFO of Auro Laboratories, effective December 18, 2024
Shaan Jain has tendered her resignation as the Chief Financial Officer (CFO) of Auro Laboratories Limited, effective December 18, 2024. In her resignation letter, she cited personal reasons as the cau...